M
Maria E. L. van der Burg
Researcher at Erasmus University Rotterdam
Publications - 42
Citations - 4678
Maria E. L. van der Burg is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Ovarian cancer & Debulking. The author has an hindex of 26, co-authored 42 publications receiving 4260 citations. Previous affiliations of Maria E. L. van der Burg include European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. gynecological cancer cooperative group of the european organization for research and treatment of cancer
Maria E. L. van der Burg,Mat van Lent,Marc Buyse,A. Kobierska,Nicoletta Colombo,G. Favalli,A. J. Lacave,M. Nardi,J. Renard,Sergio Pecorelli +9 more
TL;DR: Debulking surgery significantly lengthened progression-free and overall survival and the risk of death was reduced by one third, after adjustment for a variety of prognostic factors.
Journal ArticleDOI
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Gordon J. S. Rustin,Maria E. L. van der Burg,Clare L. Griffin,David Guthrie,Alan Lamont,Gordon C Jayson,Gunnar B. Kristensen,César Mediola,Corneel Coens,Wendi Qian,Mahesh K. B. Parmar,Ann Marie Swart +11 more
TL;DR: The findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone, and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.
Journal ArticleDOI
Molecular profiling of platinum resistant ovarian cancer
Jozien Helleman,Maurice P.H.M. Jansen,Paul N. Span,Iris L. van Staveren,Leon F. A. G. Massuger,Marion E. Meijer-van Gelder,Fired C. G. J. Sweep,Patricia C. Ewing,Maria E. L. van der Burg,Gerrit Stoter,Kees Nooter,Els M.J.J. Berns +11 more
TL;DR: The findings of this study are the discovery of a gene signature that classifies the tumours, according to their response, and a 9‐gene set that determines resistance in an independent validation set that outperforms patient and tumour characteristics.
Journal ArticleDOI
Surgical Staging and Treatment of Early Ovarian Cancer: Long-term Analysis From a Randomized Trial
Baptist Trimbos,Petra Timmers,Sergio Pecorelli,Corneel Coens,K. Ven,Maria E. L. van der Burg,Antonio Casado +6 more
TL;DR: Support is found for most of the main conclusions of the original analysis, except that overall survival after optimal surgical staging was improved, even among patients who received adjuvant chemotherapy, and the benefit from adjUvant chemotherapy appeared to be restricted to patients with nonoptimal surgical staging.